Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Cara Therapeutics Fell 28.5% in December

By Cory Renauer - Updated Apr 16, 2019 at 10:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The abuse-proof-opioid developer was swept downstream with the rest of its peers.

What happened

Shares of Cara Therapeutics (CARA 3.09%), a pre-commercial-stage biopharmaceutical company, slid 28.5% in December, according to data from S&P Global Market Intelligence. During a dismal month for small-cap biotech stocks, investors forgot about the sorely needed new opioid headed for the finish line.

Check out the latest Cara Therapeutics earnings call transcript.

So what 

From the beginning of December through Christmas Eve, the Wells Fargo Small Cap Biotechnology ETF fell 22%. Without any news during the entire month of December to help make spirits bright, it swept Cara Therapeutics downhill as well. 

Sad man looking at a downward-sloping chart.

Image source: Getty Images.

It seems investors forgot how close this company is to its first commercial drug launch. In August 2018, Cara dosed the first patient in a pivotal study with its lead candidate, Korsuva, and top-line data should be ready in a few short months.

Cara's opioid can stop pain and itch signals where they occur, but it's hardly active in the brain. That makes Korsuva a potential option for around 250,000 dialysis patients with bad kidneys that lead to chronic itching. 

Investors sensing a bargain swept in after the company announced significant progress with Korsuva's ongoing pivotal study earlier this month. Cara Therapeutics stock has already risen 20% in the year to date.

Now what

Cara Therapeutics recently completed enrollment of Korsuva's first pivotal trial, and the 12-week study should produce top-line results early in the second quarter. The odds of success seem pretty good. During a mid-stage trial, 64% of patients given Korsuva reported a worst-itch score improvement of three points or better, compared to just 29% of the placebo group.

If pivotal results fall in line with earlier observations and Korsuva earns an approval, Cara has a key marketing partner that could make its first drug launch a successful one. Fresenius Medical Care (FMS 2.00%) is a leading dialysis service provider with clinics across the country ready to sell Korsuva to patients who need it.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cara Therapeutics, Inc. Stock Quote
Cara Therapeutics, Inc.
CARA
$9.68 (3.09%) $0.29
Fresenius Medical Care AG & Co. KGaA Stock Quote
Fresenius Medical Care AG & Co. KGaA
FMS
$25.45 (2.00%) $0.50

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.